Skip to contentY
Yubo International Biotech Ltd
Y
YBGJYubo International Biotech Ltd Q1 2024 · 10-Q
Revenue$3.49K$3.49K−97.8% vs Q1 2023 Net Income-$409.51K-$409.51KN/M vs Q1 2023 EPS Diluted$0.00$0.00no prior Q1 2023 on file The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Yubo International Biotech Ltd · CIK 895464 · Engraved from SEC EDGAR
Operating Cash Flow-$120,393N/M Free Cash Flowderived-$139,317N/M Margins · derivedGross margin76.3%+39.5 pt vs Q1 2023
Operating margin-11738.0%−11535.9 pt vs Q1 2023
Net margin-11740.4%−11538.2 pt vs Q1 2023
ended Mar 31, 2024 · filed May 20, 2024 · 50 d after period end